Form 4: Ginkgo Bioworks Insider Sells Shares for Tax Withholding

Ginkgo Bioworks Holdings, Inc. reports insider Jason R. Kelly's sale of Class A Common Stock to cover tax obligations related to vesting performance-based restricted stock units.

Summary

• Jason R. Kelly, a Director and Officer of Ginkgo Bioworks Holdings, Inc., engaged in transactions involving Class A Common Stock.
• These transactions were primarily to cover tax withholding obligations arising from the vesting of Performance-Based Restricted Stock Units (PSUs).
• The vesting of PSUs on April 7, 2026, and April 8, 2026, resulted in the distribution of Class A Common Stock.
• Actual performance for these PSUs was 67% of the target, as certified by the Board of Directors' Compensation Committee.
• Kelly sold shares to cover tax withholding, a process allowed under the company's equity incentive plans, rather than discretionary trading.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as the transactions are routine for managing equity compensation taxes and do not indicate a change in the insider's fundamental view of the company's prospects, although the 67% performance achievement is a point of note.

Positives

• The transactions were executed to satisfy tax withholding obligations, indicating a standard procedure for equity compensation vesting.
• The vesting of PSUs reflects a performance-based incentive structure tied to company cash flow targets.
• The company's equity incentive plans allow for 'sell to cover' transactions to manage tax liabilities, providing flexibility for management.

Negatives

• Jason R. Kelly disposed of a significant number of shares, totaling 206,782 shares across multiple transactions between April 8 and April 9, 2026.
• The vesting of PSUs achieved only 67% of the target performance, suggesting a shortfall in the underlying company performance metric.

Risks

• The performance metrics tied to PSUs (company-wide cash flow reduction target) may not be met in future periods, impacting executive compensation.
• Significant 'sell to cover' transactions by insiders could be perceived negatively by the market, potentially impacting share price if not managed transparently.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the performance of PSUs is tied to future company cash flow, implying that future performance will be a key factor in executive compensation.

Management Comments

• Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person.
• The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a 'sell to cover' transaction.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and accepted practice for executives to manage tax liabilities associated with equity compensation vesting, particularly in growth-oriented technology companies like Ginkgo Bioworks.

Stakeholder Impact

• Shareholders: The sale of shares by an insider to cover taxes is a standard procedure and not typically indicative of a negative outlook on the company's future performance. However, the 67% achievement of performance targets might be a point of discussion.
• Employees: The structure of the PSUs and their vesting conditions highlight the performance-driven compensation model for key personnel.
• Management: Jason R. Kelly, as CEO & Founder and Director, is subject to these equity compensation and tax management processes.

Next Steps

• Continued monitoring of Ginkgo Bioworks' performance against cash flow targets, which will influence future PSU vesting and executive compensation.
• Observation of any further 'sell to cover' transactions by insiders, which are expected given the nature of equity compensation.

Key Dates

Keywords

Ginkgo Bioworks, Form 4, Insider Trading, Stock Sale, Tax Withholding, Performance-Based Restricted Stock Units, PSUs, Class A Common Stock, Jason R. Kelly, SEC Filing, Equity Compensation